KCNK3 and pulmonary arterial hypertension: Whether this is important in terms of the therapeutic strategy for patients with these mutations will depend on whether the primary action of riociguat in PAH is mediated through activation of TASK‐1 channels or whether this is an additional (but beneficial) action of riociguat (Ghofrani et al.